首页> 外文期刊>Medical oncology >Increased expression of TBX2 is a novel independent prognostic biomarker of a worse outcome in colorectal cancer patients after curative surgery and a potential therapeutic target
【24h】

Increased expression of TBX2 is a novel independent prognostic biomarker of a worse outcome in colorectal cancer patients after curative surgery and a potential therapeutic target

机译:TBX2表达增加是一种新颖的独立预后生物标志物,在根治性手术后结直肠癌患者中预后较差,并且是潜在的治疗靶标

获取原文
获取原文并翻译 | 示例
       

摘要

T-box2 (TBX2) plays a critical role in embryonic development. Recently, deregulated expression of TBX2 has been implicated in several malignancies. However, the expression and the role of TBX2 in colorectal cancer (CRC) remain unclear. In this study, we found that TBX2 was obviously up-regulated in CRC in comparison with the corresponding normal mucosa at transcriptional and protein level. Up-expression of TBX2 was significantly associated with depth of tumor invasion (P = 0.006), distant metastasis (P = 0.038), advanced AJCC stage (P = 0.008), and relapse (P = 0.003). TBX2 was a significantly prognostic factor for decreased survival and increased disease recurrence independent of tumor stage(II, III stage) and functioned as a biomarker to identify prognosis of patients with CRC (OS: HR 2.154; 95 % CI 1.019-4.551; P = 0.044, DFS: HR 2.253; 95 % CI 1.109-4.575; P = 0.025). Furthermore, TBX2 could serve as a potential target of cancer drug therapy.
机译:T-box2(TBX2)在胚胎发育中起关键作用。最近,TBX2的表达失调与多种恶性肿瘤有关。但是,TBX2在结直肠癌(CRC)中的表达及其作用尚不清楚。在这项研究中,我们发现与相应的正常黏膜在转录和蛋白质水平上相比,TBX2在CRC中明显上调。 TBX2的高表达与肿瘤浸润深度(P = 0.006),远处转移(P = 0.038),晚期AJCC分期(P = 0.008)和复发(P = 0.003)密切相关。 TBX2是降低生存率和增加疾病复发的重要预后因素,而与肿瘤阶段(II,III期)无关,并且可作为生物标志物来鉴定CRC患者的预后(OS:HR 2.154; 95%CI 1.019-4.551; P = 0.044,DFS:HR 2.253; 95%CI 1.109-4.575; P = 0.025)。此外,TBX2可以作为癌症药物治疗的潜在靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号